FDA Prepares to Refuse ANDAs with Incomplete Impurity Profiles
This article was originally published in The Gold Sheet
FDA is about to take a stand on impurity thresholds in ANDAs. Generics firms will no longer be able to file applications before dealing with excessive impurities.
Register for our free email digests: